PPCB (NASDAQ:PPCB) Announces Earnings Results
by Doug Wharley · The Cerbat GemPPCB (NASDAQ:PPCB – Get Free Report) released its earnings results on Thursday. The company reported ($0.28) earnings per share (EPS) for the quarter, FiscalAI reports.
PPCB Stock Performance
Shares of PPCB stock traded down $0.00 during trading hours on Friday, hitting $0.07. 543,336 shares of the company were exchanged, compared to its average volume of 2,910,541. The company’s 50 day simple moving average is $0.11. The stock has a market capitalization of $1.09 million, a price-to-earnings ratio of -0.01 and a beta of 3.59. PPCB has a fifty-two week low of $0.07 and a fifty-two week high of $10.81.
PPCB shares are scheduled to reverse split on Monday, May 18th. The 1-25 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, May 17th.
Analysts Set New Price Targets
Separately, Weiss Ratings raised PPCB from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.
Check Out Our Latest Report on PPCB
About PPCB
Propanc Biopharma, Inc is a healthcare company. It focuses on the development of cancer treatments for pancreatic, ovarian and colorectal cancer primarily in Australia. The Company’s products include PRP and PRP-DCM. Propanc Biopharma, Inc, formerly known as Propanc Health Group Corporation, is based in Camberwell, Australia.